Oxytocin


West-ward Pharmaceuticals Corp
Human Prescription Drug
NDC 0143-9742
Oxytocin is a human prescription drug labeled by 'West-ward Pharmaceuticals Corp'. National Drug Code (NDC) number for Oxytocin is 0143-9742. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Oxytocin drug includes Oxytocin - 10 [USP'U]/mL . The currest status of Oxytocin drug is Active.

Drug Information:

Drug NDC: 0143-9742
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Oxytocin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Oxytocin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: West-ward Pharmaceuticals Corp
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:OXYTOCIN - 10 [USP'U]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAMUSCULAR
INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Feb, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 20 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA200219
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:West-Ward Pharmaceuticals Corp
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:238013
1791721
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000009705
N0000175828
M0015703
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:1JQS135EYN
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Oxytocic [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Uterine Smooth Muscle Contraction or Tone [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Oxytocin [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Increased Uterine Smooth Muscle Contraction or Tone [PE]
Oxytocic [EPC]
Oxytocin [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0143-9742-2525 VIAL in 1 CARTON (0143-9742-25) / 10 mL in 1 VIAL (0143-9742-01)13 Feb, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Oxytocin oxytocin oxytocin oxytocin chlorobutanol acetic acid water oxytocin oxytocin oxytocin oxytocin chlorobutanol acetic acid water

Drug Interactions:

Drug interactions severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. cyclopropane anesthesia may modify oxytocin’s cardiovascular effects, so as to produce unexpected results such as hypotension. maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.

Boxed Warning:

Important notice oxytocin injection, usp (synthetic) is indicated for the medical rather than the elective induction of labor. available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications.

Indications and Usage:

Indications and usage important notice oxytocin injection, usp (synthetic) is indicated for the medical rather than the elective induction of labor. available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. antepartum oxytocin injection, usp (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. it is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indica
ted; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. in the first trimester, curettage is generally considered primary therapy. in second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. other means of therapy, however, may be required in such cases. postpartum oxytocin injection, usp (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.

Warnings:

Warnings oxytocin injection (synthetic) when given for induction or stimulation of labor, must be administered only by the intravenous route, and with adequate medical supervision in a hospital.

General Precautions:

General all patients receiving intravenous oxytocin must be under continuous observation by trained personnel with a thorough knowledge of the drug and qualified to identify complications. a physician qualified to manage any complications should be immediately available. when properly administered, oxytocin should stimulate uterine contractions similar to those seen in normal labor. overstimulation of the uterus by improper administration can be hazardous to both mother and fetus. even with proper administration and adequate supervision, hypertonic contractions can occur in patients whose uteri are hypersensitive to oxytocin. except in unusual circumstances, oxytocin should not be administered in the following conditions: prematurity, borderline cephalopelvic disproportion, previous major surgery on the cervix or uterus including caesarean section, overdistention of the uterus, grand multiparity or invasive cervical carcinoma. because of the variability of the combinations of factors w
hich may be present in the conditions above, the definition of “unusual circumstances” must be left to the judgement of the physician. the decision can only be made by carefully weighing the potential benefits which oxytocin can provide in a given case against rare but definite potential for the drug to produce hypertonicity or tetanic spasm. maternal deaths due to hypertensive episodes, subarachnoid hemorrhage, rupture of the uterus and fetal deaths due to various causes have been reported associated with the use of parenteral oxytocic drugs for induction of labor and for augmentation in the first and second stages of labor. oxytocin has been shown to have an intrinsic antidiuretic effect, acting to increase water reabsorption from the glomerular filtrate. consideration should, therefore, be given to the possibility of water intoxication, particularly when oxytocin is administered continuously by infusion and the patient is receiving fluids by mouth.

Dosage and Administration:

Dosage and administration dosage of oxytocin is determined by uterine response. the following dosage information is based upon the various regimens and indications in general use. induction or stimulation of labor intravenous infusion (drip method) is the only acceptable method of administration for the induction or stimulation of labor. accurate control of the rate of infusion flow is essential. an infusion pump or other such device and frequent monitoring of strength of contractions and fetal heart rate are necessary for the safe administration of oxytocin for the induction or stimulation of labor. if uterine contractions become too powerful, the infusion can be abruptly stopped, and oxytocic stimulation of the uterine musculature will soon wane. an intravenous infusion of a non-oxytocin containing solution should be started. physiologic electrolyte solutions should be used except under unusual circumstances. to prepare the usual solution for intravenous infusion - one ml (10 units)
is combined aseptically with 1,000 ml of a non-hydrating diluent. the combined solution, rotated in the infusion bottle to insure thorough mixing, contains 10 mu/ml. add the container with dilute oxytocic solution to the system through the use of a constant infusion pump or other such device to control accurately the rate of infusion. the initial dose should be no more than 1 to 2 mu/min. the dose may be gradually increased in increments of no more than 1 to 2 mu/min, until a contraction pattern has been established which is similar to normal labor. the fetal heart rate, resting uterine tone, and the frequency, duration, and force of contractions should be monitored. the oxytocin infusion should be discontinued immediately in the event of uterine hyperactivity or fetal distress. oxygen should be administered to the mother. the mother and fetus must be evaluated by the responsible physician. control of postpartum uterine bleeding intravenous infusion (drip method) – to control postpartum bleeding, 10 to 40 units of oxytocin may be added to 1,000 ml of a nonhydrating diluent and run at a rate necessary to control uterine atony. intramuscular administration – 1 ml (10 units) of oxytocin can be given after delivery of the placenta. treatment of incomplete or inevitable abortion intravenous infusion with physiologic saline solution, 500 ml, or 5% dextrose in physiologic saline solution to which 10 units of oxytocin have been added should be infused at a rate of 20 to 40 drops/minute. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications:

Contraindications oxytocin injection (synthetic) is contraindicated in any of the following conditions: significant cephalopelvic disproportion; unfavorable fetal positions or presentations which are undeliverable without conversion prior to delivery, i.e., transverse lies; in obstetrical emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention; in cases of fetal distress where delivery is not imminent; prolonged use in uterine inertia or severe toxemia; hypertonic uterine patterns; patients with hypersensitivity to the drug; induction or augmentation of labor in those cases where vaginal delivery is contraindicated, such as cord presentation or prolapse, total placenta previa, and vasa previa.

Adverse Reactions:

Adverse reactions the following adverse reactions have been reported in the mother: anaphylactic reaction nausea postpartum hemorrhage vomiting cardiac arrhythmia premature ventricular contractions fatal afibrinogenemia pelvic hematoma excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction or rupture of the uterus. the possibility of increased blood loss and afibrinogenemia should be kept in mind when administering the drug. severe water intoxication with convulsions and coma has occurred, and is associated with a slow oxytocin infusion over a 24-hour period. maternal death due to oxytocin-induced water intoxication has been reported. the following adverse reactions have been reported in the fetus or infant: due to induced uterine mobility due to use of oxytocin in the mother bradycardia neonatal retinal hemorrhage premature ventricular contractions and other arrhythmias low apgar scores at five minutes permanent cns or brain da
mage neonatal jaundice fetal death

Adverse Reactions Table:

Anaphylactic reaction Nausea
Postpartum hemorrhage Vomiting
Cardiac arrhythmia Premature ventricular contractions
Fatal afibrinogenemia Pelvic hematoma

Due to induced uterine mobility Due to use of oxytocin in the mother
Bradycardia Neonatal retinal hemorrhage
Premature ventricular contractions and other arrhythmias Low Apgar scores at five minutes
Permanent CNS or brain damage Neonatal jaundice
Fetal death

Drug Interactions:

Drug interactions severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. cyclopropane anesthesia may modify oxytocin’s cardiovascular effects, so as to produce unexpected results such as hypotension. maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.

Use in Pregnancy:

Pregnancy category c there are no known indications for use of oxytocin in the first and second trimester of pregnancy other than in relation to spontaneous or induced abortion. based on the wide experience with this drug and its chemical structure and pharmacological properties, it would not be expected to present a risk of fetal abnormalities when used as indicated. nonteratogenic effects- see adverse reactions in the fetus or infant. labor and delivery- see indications and usage .

Overdosage:

Overdosage overdosage with oxytocin injection (synthetic) depends essentially on uterine hyperactivity whether or not due to hypersensitivity to this agent. hyperstimulation with strong (hypertonic) or prolonged (tetanic) contractions, or a resting tone of 15 to 20 mm h 2 o or more between contractions can lead to tumultuous labor, uterine rupture, cervical and vaginal lacerations, postpartum hemorrhage, uteroplacental hypoperfusion and variable deceleration of fetal heart, fetal hypoxia, hypercapnia or death. water intoxication with convulsions, which is caused by the inherent antidiuretic effect of oxytocin, is a serious complication that may occur if large doses (40 to 50 milliunits/minute) are infused for long periods. management consists of immediate discontinuation of oxytocin, and symptomatic and supportive therapy.

Description:

Description each ml of oxytocin injection, usp (synthetic), intended for intravenous infusion or intramuscular injection, possesses an oxytocic activity equivalent to 10 usp oxytocin units and contains chlorobutanol (chloral derivative) 0.5%. this product may contain up to 12.5% decomposition products/‌impurities. oxytocin injection (synthetic) is a sterile, clear, colorless solution of oxytocin in water for injection, usp prepared by synthesis. acetic acid may have been added for ph adjustment (ph 3.0 - 5.0). the structural formula is: structural formula

Clinical Pharmacology:

Clinical pharmacology oxytocin injection (synthetic) acts on the smooth muscle of the uterus to stimulate contractions; response depends on the uterine threshold of excitability. it exerts a selective action on the smooth musculature of the uterus, particularly toward the end of pregnancy, during labor and immediately following delivery. oxytocin stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions and raises the tone of the uterine musculature. synthetic oxytocin does not possess the cardiovascular effects, such as elevation of blood pressure, as exhibited by vasopressin found in posterior pituitary injection.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility there are no animal or human studies on the carcinogenicity and mutagenicity of this drug, nor is there any information on its effect on fertility.

How Supplied:

How supplied oxytocin injection, usp (synthetic) is supplied as follows: ndc 0143-9743-25 package of 25. 1 ml fill in a 2 ml vial, 10 usp units per ml. ndc 0143-9742-25 package of 25. 10 ml fill in a 10 ml vial, 10 usp units per ml. discard unused portion. use only if solution is clear and seal is intact. store at 20º to 25ºc (68º to 77ºf) [see usp controlled room temperature]. do not permit to freeze.

Package Label Principal Display Panel:

Principal display panel ndc 0143-9743-01 oxytocin injection, usp (synthetic) 10 usp units/ml sterile for iv (infusion) or im use rx only 1 ml single dose vial store at 20º to 25ºc (68º to 77ºf) [see usp controlled room temperature]. usual dosage: see package insert. note: oversize vial ndc 0143-9743-01 oxytocin injection, usp (synthetic) 10 usp units/ml sterile for iv (infusion) or im use rx only 1 ml single dose vial store at 20º to 25ºc (68º to 77ºf) [see usp controlled room temperature]. usual dosage: see package insert. note: oversize vial

Principal display panel ndc 0143-9742-01 oxytocin injection, usp (synthetic) 100 usp units/10 ml (10 usp units/ml) for iv (infusion) or im use rx only 10 ml multiple dose vial each ml contains oxytocin activity equivalent to 10 usp oxytocin units; chlorobutanol 0.5%; water for injection q.s. acetic acid may have been added for ph adjustment. usual dosage: see package insert. store at 20º to 25ºc (68º to 77ºf) [see usp controlled room temperature]. do not permit to freeze. ndc 0143-9742-01 oxytocin injection, usp (synthetic) 100 usp units/10 ml (10 usp units/ml) for iv (infusion) or im use rx only 10 ml multiple dose vial each ml contains oxytocin activity equivalent to 10 usp oxytocin units; chlorobutanol 0.5%; water for injection q.s. acetic acid may have been added for ph adjustment. usual dosage: see package insert. store at 20º to 25ºc (68º to 77ºf) [see usp controlled room temperature]. do not permit to freeze.

Serialization image layout 1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.